1. Top
  2. Business Overview
  3. Main R&D Activities

Main R&D Activities

ActivityOutlineObjective
In-house programWe aim at optimization of inhibitors for IL-6, tumor angiogenesis, Notch1, IgE, and tubulin polymerization. We have identified IL-6 inhibitors that bind to IL-6 and modulate IL-6/IL-6R interaction, and hope to accelerate its optimization with a research partner.Lead optimization with an alliance partner
Collaborative drug discovery researches of small molecules for new targetsWe conduct drug discovery researches of small molecules for new targets proposed by Pharma or Interprotein in collaboration with Pharma. Now, we are seeking partners that conduct drug discovery researches for TIM-3, KIR, and NKG2A (immune checkpoints), Runx1 (leukemia-related transcription factor), and gp130 (key molecule in IL-6 signaling) in collaboration.Conduct of drug discovery researches in collaboration with alliance partners
Collaborative drug discovery researches of HLHP for new targetsWe conduct drug discovery researches of HLHP for new targets proposed by Pharma or Interprotein in collaboration with Pharma. Now, we are seeking partners that conduct drug discovery researches for TIM-3, KIR, NKG2A, and gp130 in collaboration. HLHP is also applicable to substitution for antibody in antibody-drug conjugate (ADC).Conduct of drug discovery researches in collaboration with alliance partners

In house project

ProjectDomainStageNote
Tumor angiogenesis inhibitorOncology
(tumor angiogenesis)
Lead optimizationWe have identified compounds that inhibit VEGF-induced proliferation of HUVEC and suppress tumor growth in xenograft models.
MOA is now being verified.
IL-6 inhibitorAutoimmune Inflammation OncologyLead generationWe have identified compounds that modulate IL-6/IL-6R interaction in a cell-free system (MOA has been almost fully verified).
IgE inhibitorAllergyHit validationWe have identified compounds that inhibit IgE-induced degranulation of basophils. MOA has been partly verified.
Notch1 inhibitorOncology
Hematology
Lead generationWe have identified compounds that inhibit Notch1-relevant transcription and suppress tumor growth in a xenograft model. MOA has been partly verified.
Tubulin polymerization inhibitorOncology
Hematology
Lead generationWe have identified compounds that inhibit tubulin polymerization in a cell-free system and suppress tumor growth in xenograft models. MOA has been almost fully verified.

New Target

ProjectDomainNote
TIM-3 inhibitorOncology
Immune Check Point
We have identified TIM-3 binding peptides and are investigating those effects on TIM-3 binding to HMGB1, galectin-9 and CEACAM1.
NKG2A/HLA-E/CD94 inhibitorOncology
Immune Check Point
We have designed peptides that are expected to bind NKG2A and inhibit NKG2A binding to HLA-E/CD94.
KIR/HLA-C inhibitorOncology
Immune Check Point
We have designed peptides that are expected to bind KIR and inhibit KIR binding to HLA-C.
gp130 inhibitorAutoimmune Inflammation OncologyWe have selected hit candidates for small molecule gp130/IL-6 interaction (intra-trimer) modulator, and also designed peptide gp130/IL-6 binding (inter-trimer) inhibitor.
RUNX1/CBFβ inhibitorOnco-hematologyWe have identified the compounds that bind to RUNX1 and inhibit RUNX1/CBFβ binding to DNA with IC50 values of less than 1μM.